Corpus overview


MeSH Disease

Abdominal Pain (39)

Disease (26)

Fever (24)

Infections (24)

Diarrhea (24)

Human Phenotype

Abdominal pain (39)

Fever (24)

Diarrhea (22)

Cough (19)

Fatigue (14)


    displaying 1 - 10 records in total 39
    records per page

    Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia HP

    Authors: Margaret Cho; Weiguo Liu; Sophie Balzora; Yvelisse Suarez; Deepthi Hoskoppal; Neil D Theise; Wenqing Cao; Suparna A Sarkar

    doi:10.1101/2020.07.29.20164558 Date: 2020-08-07 Source: medRxiv

    Gastrointestinal (GI) symptoms of SARS-CoV2/COVID-19 in the form of anorexia MESHD anorexia HP, nausea MESHD nausea, vomiting HP, vomiting MESHD, abdominal pain MESHD abdominal pain HP and diarrhea MESHD diarrhea HP are usually preceeded by respiratory manifestations and are associated with a poor prognosis. Hematochezia HP is an uncommon clinical presentation of COVID-19 disease MESHD and we hypothesize that older patients with significant comorbidites ( obesity MESHD obesity HP and cardiovascular) and prolonged hospitalization are suspectible to ischemic injury to the bowel. We reviewed the clinical course, key laboratory data including acute phase reactants, drug/medication history in two elderly TRANS male TRANS patients admitted for COVID-19 respiratory failure HP. Both patients had a complicated clinical course and suffered from hematochezia HP and acute blood SERO loss anemia MESHD anemia HP requiring blood SERO transfusion around day 40 of their hospitalization. Colonoscopic impressions were correlated with the histopathological findings in the colonic biopies and changes compatible with ischemia MESHD to nonspecific acute inflammation MESHD, edema MESHD edema HP and increased eosinophils in the lamina propria were noted.Both patients were on anticoagulants, multiple antibiotics and antifungal agents due to respiratory infections MESHD at the time of lower GI bleeding. Hematochezia HP resolved spontaneously with supportive care. Both patients eventually recovered and were discharged. Elderly TRANS patients with significant comorbid conditions are uniquely at risk for ischemic injury to the bowel. Hypoxic conditions due to COVID-19 pneumonia MESHD pneumonia HP and respiratory failure HP, compounded by preexisting cardiovascular complications, and/or cytokine storm orchestrated by the viral infection MESHD leading to alteration in coagulation profile and/or drug/medication injury can be difficult to distinguish in these critically ill patients. Presentation of hematochezia HP may further increase the mortality and morbidity of COVID-19 patients, and prompt consultation and management by gastroenterology is therefore warranted.

    Ontology-based annotation and analysis of COVID-19 phenotypes

    Authors: Yang Wang; Fengwei Zhang; Hong Yu; Xianwei Ye; Yongqun He

    id:2008.02241v1 Date: 2020-08-05 Source: arXiv

    The epidemic of COVID-19 has caused an unpredictable and devastated disaster to the public health in different territories around the world. Common phenotypes include fever MESHD fever HP, cough MESHD cough HP, shortness of breath, and chills MESHD chills HP. With more cases investigated, other clinical phenotypes are gradually recognized, for example, loss of smell, and loss of tastes. Compared with discharged or cured patients, severe or died patients often have one or more comorbidities, such as hypertension MESHD hypertension HP, diabetes, and cardiovascular disease MESHD. In this study, we systematically collected and analyzed COVID-19-related clinical phenotypes from 70 articles. The commonly occurring 17 phenotypes were classified into different groups based on the Human Phenotype Ontology (HPO). Based on the HP classification, we systematically analyze three nervous phenotypes (loss of smell, loss of taste, and headache MESHD headache HP) and four abdominal phenotypes ( nausea MESHD nausea, vomiting HP, vomiting MESHD, abdominal pain MESHD abdominal pain HP, and diarrhea MESHD diarrhea HP) identified in patients, and found that patients from Europe and USA turned to have higher nervous phenotypes and abdominal phenotypes than patients from Asia. A total of 23 comorbidities were found to commonly exist among COVID-19 patients. Patients with these comorbidities such as diabetes and kidney failure had worse outcomes compared with those without these comorbidities.

    Fighting COVID-19 spread among nursing home residents even in absence of molecular diagnosis: a retrospective cohort study.

    Authors: Alessio Strazzulla; Paul Tarteret; Maria Concetta Postorino; Marie Picque; Astrid de Pontfarcy; Nicolas Vignier; Catherine Chakvetadze; Coralie Noel; Cecile Drouin; Zine Eddine Benguerdi; Sylvain Diamantis

    doi:10.21203/ Date: 2020-07-30 Source: ResearchSquare

    Background Access to molecular diagnosis was limited out-of-hospital in France during the 2020 coronavirus disease MESHD 2019 (COVID-19) epidemic. This study describes the evolution of COVID-19 outbreak in a nursing home in absence of molecular diagnosis. Methods A monocentric prospective study was conducted in a French nursing home from March 17th, 2020 to June 11th, 2020. Because of lack of molecular tests for severe acute respiratory syndrome MESHD 2 (SARS-Cov2) infection MESHD, probable COVID-19 cases were early identified considering only respiratory and not-respiratory symptoms and therefore preventing measures and treatments were enforced. Once available, serology tests were performed at the end of the study.A chronologic description of new cases and deaths MESHD was made together with a description of COVID-19 symptoms. Data about personal characteristics and treatments were collected and the following comparisons were performed: i) probable COVID-19 cases vs asymptomatic TRANS residents; ii) SARS-Cov2 seropositive residents vs seronegative residents. Results Overall, 32/66 (48.5%) residents and 19/39 (48.7%) members of health-care personnel were classified as probable COVID-19 cases. A total of 34/61 (55.7%) tested residents resulted seropositive. Death MESHD occurred in 4/66 (6%) residents. Diagnosis according to symptoms had 65% of sensitivity SERO, 78% of specificity, 79% of positive predictive value SERO and 64% of negative predictive value SERO.In resident population, the following symptoms were registered: 15/32 (46.8%) lymphopenia MESHD lymphopenia HP, 15/32 (46.8%) fever MESHD fever HP, 8/32 (25%) fatigue MESHD fatigue HP, 8/32 (25%) cough MESHD cough HP, 6/32 (18.8%) diarrhoea, 4/32 (12.5%) severe respiratory distress HP requiring oxygen therapy, 4/32 (12.5%) fall HP, 3/32 (9.4%) conjunctivitis MESHD conjunctivitis HP, 2/32 (6.3%) abnormal pulmonary noise at chest examination and 2/32 (6,25%) abdominal pain MESHD abdominal pain HP. Probable COVID-19 cases were older (81.3 vs 74.9; p=0.007) and they had higher prevalence SERO of atrial fibrillation MESHD atrial fibrillation HP (8/32, 25% vs 2/34, 12%; p=0.030); insulin treatment (4/34, 12% vs 0, 0%; p=0.033) and positive SARS-Cov2 serology (22/32, 69% vs 12/34, 35%; p=0.001) than asymptomatic TRANS residents. Seropositive residents had lower prevalence SERO of diabetes (4/34, 12% vs 9/27, 33%; p=0.041) and angiotensin-converting-enzyme inhibitors’ intake (1/34, 1% vs 5/27, 19%; p=0.042). Conclusions During SARS-Cov2 epidemic, early detection of respiratory and not-respiratory symptoms allowed to enforce extraordinary measures. They achieved limiting contagion and deaths MESHD among nursing home residents, even in absence of molecular diagnosis.

    CCOFEE-GI Study: Colombian COVID19 First Experience in Gastroentrology. Characterization of digestive manifestations in patients diagnosed with COVID-19 at a highly complex institution in Bogota D.C., Colombia


    doi:10.1101/2020.07.24.20161604 Date: 2020-07-24 Source: medRxiv

    The current pandemic caused by SARS-CoV-2 has posed an important threat to the human health, healthcare systems, economy, and structure of societies. In Colombia, the first case was diagnosed on March 6, 2020 , with exponential progressive growth, and there were >200,000 confirmed cases TRANS as of July 20, 2020, in this cross-sectional, analytical, and observational study, we focused on the demographic, epidemiologic, and clinical characteristics of patients with confirmed SARS-CoV-2 infection MESHD at a highly complex institution in Latinamerica, with special emphasis on gastrointestinal symptoms. Methods: Demographic and clinical data were collected, results related to the outcomes such as hospitalization time, admission to ICU, need for orotracheal intubation, and death MESHD were also included. Statistical analyses were conducted using Stata software V.15. Results: We included 72 patients RT-PCR positive for SARS-CoV-2 (34 women and 38 men) with age TRANS 47.5 17.7 years; 17 (23.6%) presented at least one of the gastrointestinal symptoms ( nausea MESHD nausea/vomiting HP/ vomiting MESHD, abdominal pain MESHD abdominal pain HP, and/or diarrhea MESHD diarrhea HP). 13 (76.47%) presented with diarrhea MESHD diarrhea HP, 29.41% with nausea MESHD nausea/vomiting HP/ vomiting MESHD, and five (29.41%) with abdominal pain MESHD abdominal pain HP. Diarrhea MESHD Diarrhea HP in 18.06% of all those infected with SARS-CoV-2 at the time of consultation, which was the most common digestive symptom. No significant differences were observed in requirement for endotracheal intubation, hospitalization, ICU admission, and fatal outcome between the NGIS and GIS groups (p:0.671, 0.483, 1,000, and 1,000). Conclusion: In our study, patients with gastrointestinal symptoms had no significant differences in disease MESHD severity, admission to ICU or death MESHD compared to those who did not have such symptoms.

    Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19

    Authors: SARAH, M M LOFGREN; Melanie R Nicol; Ananta S Bangdiwala; Katelyn A Pastick; Elizabeth C Okafor; Caleb P Skipper; Matthew F Pullen; Nicole W Engen; Mahsa Abassi; Darlisha A Williams; Alanna A Nascene; Margaret L Axelrod; Sylvian A Lother; Lauren J MacKenzie; Glen Drobot; Nicole Marten; Matthew P Cheng; Ryan Zarychanshi; Ilan S Schwartz; Michael Silverman; Zain Chagla; Lauren E Kelley; Emily G McDonald; Todd C Lee; Katherine Huppler Hullsiek; David R Boulware; Radha Rajasingham

    doi:10.1101/2020.07.16.20155531 Date: 2020-07-23 Source: medRxiv

    Introduction: Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from three outpatient randomized clinical trials. Methods: We conducted three randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. Results: We enrolled 2,795 participants. The median age TRANS of research participants was 40 (IQR 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with placebo. The most common side effects were upset stomach or nausea MESHD nausea HP (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea MESHD diarrhea HP, vomiting MESHD vomiting HP, or abdominal pain MESHD abdominal pain HP (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias HP, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths MESHD occurred. Conclusion: Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths MESHD occurred related to hydroxychloroquine. Randomized clinical trials can safely investigate whether hydroxychloroquine is efficacious for COVID-19.

    Direct-to-Consumer Chat-Based Remote Care Before and During the COVID-19 Outbreak

    Authors: Dan Zeltzer; Alina Vodonos Zilberg; Yehuda Edo Paz; Roy Malka

    doi:10.1101/2020.07.14.20153775 Date: 2020-07-16 Source: medRxiv

    Objective. To compare the patient population, common complaints, and physician recommendations in direct-to-consumer chat-based consults, before and during the COVID-19 outbreak. Data sources. Data on patient characteristics, patient complaints, and physician recommendations from 36,864 chat-based telemedicine consults with physicians in an online-clinic by patients from across the United States between April 2019 and April 2020. Study Design. We perform a retrospective analysis comparing patient characteristics, visit characteristics, and physician recommendation before and after the COVID-19 outbreak. We examine patient age TRANS and gender TRANS, visit time, patient chief complains, and physician medical recommendation (including prescription drugs, reassurance, and referrals). Principal Findings. Before March 2020, most patients were female TRANS (75 percent) and 18-44 years old (89 percent). Common complaints such as abdominal pain MESHD abdominal pain HP, dysuria MESHD dysuria HP, or sore throat suggested minor acute conditions. Most cases (67 percent) were resolved remotely, mainly via prescriptions; a minority were referred. Since March 2020, the COVID-19 emergency MESHD has led to a sharp (fourfold) increase in case volume, including more males TRANS (from 25 to 29 percent), patients aged TRANS 45 and older (from 11 to 17 percent), and more cases involving mental health complaints and complaints related to COVID-19. Across all symptoms, significantly more cases (78 percent) have been resolved remotely. Conclusions. The COVID-19 outbreak in the United States has been associated with a sharp increase in the use of chat-based telemedicine services, including by new patient demographics, an increase in both COVID-19 and mental health complains, and an increase in remote case resolutions.

    Longitudinal symptom dynamics of COVID-19 infection MESHD in primary care

    Authors: Barak Mizrahi; Smadar Shilo; Hagai Rossman; Nir Kalkstein; Karni Marcus; Yael Barer; Ayya Keshet; Na'ama Shamir-Stein; Varda Shalev; Anat Ekka Zohar; Gabriel Chodick; Eran Segal

    doi:10.1101/2020.07.13.20151795 Date: 2020-07-14 Source: medRxiv

    Objective : Data regarding the clinical characteristics of COVID-19 infection MESHD is rapidly accumulating. However, most studies thus far are based on hospitalized patients and lack longitudinal follow up. As the majority of COVID-19 cases are not hospitalized, prospective studies of symptoms in the population presenting to primary care are needed. Here, we assess the longitudinal dynamic of clinical symptoms in non-hospitalized individuals prior to and throughout the diagnosis of SARS-CoV-2 infection MESHD. Design Data on symptoms were extracted from electronic health records (EHR) consisting of both results of PCR tests and symptoms recorded by primary care physicians, and linked longitudinal self reported symptoms. Setting The second largest Health Maintenance Organization in Israel , Maccabi Health Services Participants From 1/3/2020 to 07/06/2020, information on symptoms from either surveys or primary care visits was available for 206,377 individuals, including 2,471 who tested positive for COVID-19. Main Outcomes Longitudinal prevalence SERO of clinical symptoms in COVID-19 infection MESHD diagnosed by PCR testing for SARS-CoV-2 from nasopharyngeal swabs. Results: In adults TRANS, the most prevalent symptoms recorded in EHR were cough MESHD cough HP (11.6%), fever MESHD fever HP (10.3%), and myalgia MESHD myalgia HP (7.7%) and the most prevalent self-reported symptoms were cough MESHD cough HP (21%), fatigue MESHD fatigue HP (19%) and rhinorrhea HP and/or nasal congestion (17%). In children TRANS, the most prevalent symptoms recorded in the EHR were fever MESHD fever HP (7%), cough MESHD cough HP (5.5%) and abdominal pain MESHD abdominal pain HP (2.4%) . Emotional disturbances were documented in 15.9% of the positive adults TRANS and 4.2% of the children TRANS. Loss of taste and smell, either self-reported or documented by a physician, 3 weeks prior to testing, were the most discriminative symptoms in adults TRANS (OR =11.18 and OR=5.47 respectively). Additional symptoms included self reported headache MESHD headache HP (OR = 2.03) and fatigue MESHD fatigue HP (OR = 1.73) and a documentation of syncope MESHD syncope HP, rhinorrhea HP (OR = 2.09 for both ) and fever MESHD fever HP (OR= 1.62 ) by a physician. Mean time to recovery TRANS was 23.5 +- 9.9 days. Children TRANS had a significantly shorter disease MESHD duration (21.7 +- 8.8 days, p-value=0.01). Several symptoms, including fatigue MESHD fatigue HP, myalgia MESHD myalgia HP, runny nose and shortness of breath were reported weeks after recovery. Conclusions As the COVID-19 pandemic progresses rapidly worldwide, obtaining accurate information on symptoms and their progression is of essence. Our study shed light on the full clinical spectrum of symptoms experienced by infected individuals in primary care, and may alert physicians for the possibility of COVID-19 infection MESHD.

    Unusual Presentation of Kawasaki Disease MESHD with Multisystem Inflammation MESHD and Antibodies SERO Against Severe Acute Respiratory Syndrome MESHD Coronavirus 2: A Case Report

    Authors: Haena Kim; Jung Yeon Shim; Jae-Hoon Ko; Aram Yang; Jae Won Shim; Deok Soo Kim; Hye Lim Jung; Ji Hee Kwak; In Suk Sol

    doi:10.21203/ Date: 2020-07-12 Source: ResearchSquare

    Background: Since mid-April 2020, cases of multisystem inflammatory syndrome MESHD in children TRANS (MIS-C) associated with coronavirus disease MESHD (COVID-19) that mimic Kawasaki disease MESHD (KD) have been reported in Europe and North America. However, no cases have been in East Asia, where KD is more prevalent.Case presentation: A previously healthy 11-year-old boy was admitted with a 4-day history of fever MESHD fever HP and abdominal pain MESHD abdominal pain HP. He had no contact history to any patient with COVID-19. Blood SERO acute inflammatory markers were highly elevated. He was treated with antibiotics for suspected bacterial enteritis MESHD, but he suddenly developed hypotension MESHD hypotension HP. Inotropics and intravenous immunoglobulin were administered to manage septic shock MESHD shock HP. On hospitalization day 6, he developed signs and symptoms MESHD of KD (conjunctival injection, strawberry tongue HP, cracked lip, and coronary artery dilatation HP) in addition to pleural/ pericardial effusion MESHD pericardial effusion HP and mesenteric lymphadenitis MESHD lymphadenitis HP. The results of microbiologic tests, including reverse-transcription polymerase chain reaction for severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), were negative. Fluorescent immunoassay SERO and enzyme-linked immunosorbent assay SERO revealed abundant IgG antibodies SERO against SARS-CoV-2 in his serum SERO, but no IgM antibodies SERO. He was discharged successfully on day 13.Conclusion: MIS-C may occur in children TRANS with a previously asymptomatic TRANS COVID-19 infection MESHD. A high index of suspicion is required for this novel syndrome MESHD in unusual cases of KD or KD shock MESHD shock HP syndrome MESHD with multisystem inflammation MESHD, even when there is no clear history of contact or symptoms of COVID-19.

    The presentation of spontaneous splenic rupture MESHD splenic rupture HP in a COVID-19 patient: a case report

    Authors: Mohammadreza Mobayen; Saeed Yousefi; Mohammadsadegh Mousavi; Amin Shafighi Anbaran

    doi:10.21203/ Date: 2020-07-09 Source: ResearchSquare

    Introduction: Splenic rupture MESHD Splenic rupture HP is an emergency MESHD condition and the vast numbers of cases are secondary TRANS to trauma. Several underlying pathologies have also been associated with splenic rupture MESHD splenic rupture HP, such as hematological diseases MESHD, malignancies, and infectious and inflammatory diseases MESHD.Presentation of case: The patient was a 52-year-old man who referred to the Poursina Hospital in Rasht while complaining of abdominal pain MESHD abdominal pain HP from the day before hospitalization. The patient reported a history of lethargy MESHD lethargy HP, fever MESHD fever HP, and nausea MESHD nausea HP. In the examinations performed, there was a brief tenderness in the patient's epigastrium. The patient was monitored and about 12 hours after hospitalization, ill appearance, respiratory ( respiratory distress HP) symptoms, and high fever MESHD fever HP were reported for the patient. According to the examination, the patient was immediately transferred to the operating room and underwent laparotomy. During the operation, contrary to our expectations, a lot of blood SERO (about 1000 cc) was observed in the patient's abdomen. After blood SERO suctioning, the left upper quadrant (LUQ) was bleeding and the rupture MESHD of the spleen could also be observed. Therefore, a splenectomy was performed .In the examinations performed for the patient, the patient's rtPCR test confirmed COVID-19.Conclusion: The evaluation of the spontaneous splenic rupture MESHD splenic rupture HP (SSR) in our case shows that this type of risk should also be considered in patients with COVID-19 who referred to medical centers with abdominal pain MESHD abdominal pain HP, and if more cases are reported, the correctness of this process can be commented on.

    Digestive Manifestations in Patients Hospitalized with COVID-19

    Authors: B. Joseph Elmunzer; Rebecca L. Spitzer; Lydia D. Foster; Ambreen A. Merchant; Eric F. Howard; Vaishali A. Patel; Mary K. West; Emad Qayad; Rosemary Nustas; Ali Zakaria; Marc S. Piper; Jason R. Taylor; Lujain Jaza; Nauzer Forbes; Millie Chau; Luis F. Lara; Georgios I. Papachristou; Michael L. Volk; Liam G. Hilson; Selena Zhou; Vladimir M. Kushnir; Alexandria M. Lenyo; Caroline G. McLeod; Sunil Amin; Gabriela N. Kuftinec; Dhiraj Yadav; Charlie Fox; Jennifer M. Kolb; Swati Pawa; Rishi Pawa; Andrew Canakis; Christopher Huang; Laith H. Jamil; Andrew M. Aneese; Benita K. Glamour; Zachary L. Smith; Katherine A. Hanley; Jordan Wood; Harsh K. Patel; Janak N. Shah; Emil Agarunov; Amrita Sethi; Evan L. Fogel; Gail McNulty; Abdul Haseeb; Judy A. Trieu; Rebekah E. Dixon; Jeong Yun Yang; Robin B. Mendelsohn; Delia Calo; Olga C. Aroniadis; Joseph F. LaComb; James M. Scheiman; Bryan G. Sauer; Duyen T. Dang; Cyrus R. Piraka; Eric D. Shah; Heiko Pohl; William M. Tierney; Stephanie Mitchell; Ashwinee Condon; Adrienne Lenhart; Kulwinder S. Dua; Vikram S. Kanagala; Ayesha Kamal; Vikesh K. Singh; Maria Ines Pinto-Sanchez; Joy M. Hutchinson; Richard S. Kwon; Sheryl J. Korsnes; Harminder Singh; Zahra Solati; Amar R. Deshpande; Don C. Rockey; Teldon B. Alford; Valerie Durkalski; Field F. Willingham; Patrick S. Yachimski; Darwin L. Conwell; Evan Mosier; Mohamed Azab; Anish Patel; James Buxbaum; Sachin Wani; Amitabh Chak; Amy E. Hosmer; Rajesh N. Keswani; Christopher J. DiMaio; Michael S. Bronze; Raman Muthusamy; Marcia I. Canto; V. Mihajlo Gjeorgjievski; Zaid Imam; Fadi Odish; Ahmed I. Edhi; Molly Orosey; Abhinav Tiwari; Soumil Patwardhan; Nicholas G. Brown; Anish A. Patel; Collins O. Ordiah; Ian P. Sloan; Lilian Cruz; Casey L. Koza; Uchechi Okafor; Thomas Hollander; Nancy Furey; Olga Reykhart; Natalia H. Zbib; John A. Damianos; James Esteban; Nick Hajidiacos; Melissa Saul; Melanie Mays; Gulsum Anderson; Kelley Wood; Laura Mathews; Galina Diakova; Molly Caisse; Lauren Wakefield; Haley Nitchie

    doi:10.1101/2020.07.07.20143024 Date: 2020-07-09 Source: medRxiv

    Background: The prevalence SERO and significance of digestive manifestations in COVID-19 remain uncertain. Methods: Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset TRANS until discharge or death MESHD were manually abstracted from electronic health records to characterize the prevalence SERO, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. Results: A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea MESHD diarrhea HP (34%), nausea MESHD nausea HP (27%), vomiting MESHD vomiting HP (16%), and abdominal pain MESHD abdominal pain HP (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death MESHD. Conclusions: Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.